Congress Asked Whether the VA Is Ready for Psychedelic Therapy. The Answer Came Down to Trained Clinicians. Here Is What Canadian Practitioners Should Take From It

On Wednesday, November 18, 2026, the U.S. House Veterans' Affairs Subcommittee on Health held a two-and-a-half-hour oversight hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward." Officials from the Department of Veterans Affairs, researchers, the American Psychological Association and veterans' service organizations faced a bipartisan panel chaired by Rep. Mariannette Miller-Meeks, a physician, who asked one question in many forms: if a psychedelic medicine is approved in 2027, can the largest integrated health system in the United States actually deliver it?
Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.
As a Leader in Psychedelic News, ATMA CENA follows hearings like this one because the hard part of psychedelic care is no longer only the science. It is the people, the rooms and the hours. The hearing, reported the same day by Stars and Stripes, States Newsroom and Marijuana Moment, offered a frank look at that problem from a system already planning for it.
What the VA told Congress
Andrew Gradison, senior advisor to the Under Secretary for Health at the Veterans Health Administration, told the subcommittee that the VA now has 21 active clinical studies of psychedelics for mental health conditions, and that its research portfolio "has grown substantially" since an April 2026 executive order directed federal agencies to speed up psychedelic research. He pointed to a VA trial announced in August in veterans with treatment-resistant depression, and to a July memorandum of understanding between the VA and the Department of Health and Human Services.
The more striking numbers concerned readiness. Gradison said the VA has identified 10 facilities with the capacity to serve as "early implementers, educators, or sites-in-training" for any therapy the FDA approves. He would not name them all publicly but committed to giving the list to committee members within 30 days. According to States Newsroom, the VHA estimates that roughly 180,000 of the just over two million veterans with treatment-resistant depression would likely meet the criteria for such a treatment. Gradison's own assessment was blunt: "Our demand for these treatments will exceed our ability to supply them."
He explained why. These treatments are "extremely labor intensive," he said, and "dosing sessions alone can last six to eight hours." The VA has analyzed staff time and wants the first sites resourced so that psychedelic care does not have "a detrimental impact on mental health access at large." Dr. Ilse Wiechers, a VHA leader in patient care services, said the agency would proceed "in a thoughtful and phased approach." Gradison framed the VA's priorities as veteran safety, building the evidence base, and being "positioned to be the first health care system in the Nation to deliver these treatments to Veterans," while "ensuring Veteran safety above all else."
Ready to offer this in your practice?
Talk with a program advisor about ATMA CENA's training pathways and whether they fit your practice.
What the experts and veterans' groups asked for
The second panel kept returning to the workforce. Marion Coe of Pinney Associates put it most directly: "I think that having an appropriately trained workforce is the central task here." Dr. Raquel Halfond of the American Psychological Association urged the VA to plan for workforce demands, informed consent, trauma-informed care and access to licensed professionals. Dr. Mark Niciu of the University of Iowa cautioned, citing the risk-management program that governs an already-approved nasal-spray treatment, that implementation "might still take months to years" after an FDA approval. Dr. Leith States, a physician and Navy veteran, asked for clear milestones on clinical readiness.
The veterans' organizations pushed toward speed. Naomi Mathis of Disabled American Veterans asked for larger, rigorous trials within the veteran population, saying that "veterans deserve access to treatments proven safe and effective through rigorous scientific evaluation." The Veterans of Foreign Wars and the Special Forces Foundation also urged lawmakers to accelerate research. Stars and Stripes reported that veterans die by suicide at about twice the rate of non-veterans, and States Newsroom noted that nearly 6,500 veterans died by suicide in 2024, a figure Chair Miller-Meeks called "stubbornly stagnant." "Something needs to change," she said.
Ranking member Rep. Julia Brownley called the VA trials "extremely welcome news" but said the treatment "will not be a panacea for everyone." She asked whether the VA would hire additional staff to meet demand and said the VA must carefully develop criteria for private providers who want to deliver these therapies through its community care network. Rep. Herb Conaway observed that "most of them," the early sites, appeared to be "on the coast."
Expand what you can offer your patients
Our training prepares regulated professionals to deliver psychedelic-assisted therapy safely and confidently.
Why this matters for Canadian practitioners
No decision was made on November 18. A hearing cannot approve a drug, fund a clinic or license a therapist. Its value for Canadian readers lies in hearing a very large health system say, on the record, that the limiting factor will be trained people and clinic hours.
Canada faces the same arithmetic. If a psychedelic treatment is approved in the United States next year, as Compass Pathways' completed New Drug Application, covered on this blog on November 10, makes possible, Canadian regulators, provincial colleges and clinics will be asked how they intend to deliver sessions that can run six to eight hours, with screening, preparation and integration around them. The VA's phased plan, its early-implementer sites and Brownley's point about criteria for outside providers are all questions Canadian health authorities and clinics will have to answer in their own terms.
For nurses, psychologists, physicians and therapists, the practical takeaway is that the training conversation has moved from whether to how many and how soon. ATMA CENA's Advanced Pathways, which begin with the Psychedelic Therapy Foundations course, are built for exactly that transition. If you are considering where your own practice fits, you can explore the training options at ATMA CENA's psychedelic therapy training page or book a call with a program advisor to talk it through.
Join a national network of trained clinicians
Explore ATMA CENA's certification pathways and the CoCare clinic network with a program advisor.
Sources
- Committee Cliff Notes: Weekly Preview, Week of November 16, 2026. Office of the House Majority Leader, 2026.
- Veterans groups urge VA, Congress to prepare for FDA-approved psychedelics for mental health treatment. Stars and Stripes, 2026.
- Psychedelic mental healthcare for veterans wins bipartisan backing from US House panel. States Newsroom (Now Georgia), 2026.
- Congress Holds Hearing On Psychedelics For Military Veterans. Marijuana Moment, 2026.
- Report from U.S. House Veterans' Affairs subcommittee hearing on psychedelic-assisted therapies. The Microdose, UC Berkeley Center for the Science of Psychedelics, 2026.
- Congress Turns To Psychedelic Therapy For Veterans As VA Prepares For A Decision It Has Not Yet Made. The Hype Magazine, 2026.
Get trained in psychedelic-assisted therapy
Explore ATMA CENA locations across Canada.
- Psychedelic Therapy Training Edmonton
- Psychedelic Therapy Training Calgary
- Psychedelic Therapy Training Hamilton
- Psychedelic Therapy Training Kitchener-Waterloo
- Psychedelic Therapy Training London
- Psychedelic Therapy Training Mississauga
- Psychedelic Therapy Training Montreal
- Psychedelic Therapy Training North Bay
- Psychedelic Therapy Training Sarnia
- Psychedelic Therapy Training Saskatoon
- Psychedelic Therapy Training Vaughan
- Psychedelic Therapy Training Winnipeg